XORTX Therapeutics, Inc. (XRTX)
1.714
-0.02
(-0.91%)
USD |
NASDAQ |
Oct 02, 16:00
1.67
-0.04
(-2.58%)
After-Hours: 20:00
XORTX Therapeutics Cash from Operations (TTM) : -5.062M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.062M |
| March 31, 2026 | -2.632M |
| December 31, 2025 | -2.774M |
| September 30, 2025 | -2.917M |
| June 30, 2025 | -3.031M |
| March 31, 2025 | -2.952M |
| December 31, 2024 | -3.612M |
| September 30, 2024 | -4.091M |
| June 30, 2024 | -4.414M |
| March 31, 2024 | -5.401M |
| December 31, 2023 | -6.581M |
| September 30, 2023 | -9.082M |
| June 30, 2023 | -8.958M |
| March 31, 2023 | -9.092M |
| December 31, 2022 | -9.111M |
| September 30, 2022 | -8.449M |
| Date | Value |
|---|---|
| June 30, 2022 | -7.562M |
| March 31, 2022 | -6.402M |
| December 31, 2021 | -4.823M |
| September 30, 2021 | -1.660M |
| June 30, 2021 | -1.689M |
| March 31, 2021 | -1.127M |
| December 31, 2020 | -0.5373M |
| September 30, 2020 | -0.5907M |
| June 30, 2020 | -0.4912M |
| March 31, 2020 | -0.3812M |
| December 31, 2019 | -0.135M |
| September 30, 2019 | -0.2027M |
| June 30, 2019 | -0.3647M |
| March 31, 2019 | -0.5479M |
| December 31, 2018 | -0.7165M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Lexaria Bioscience Corp. | -7.426M |
| InMed Pharmaceuticals, Inc. | -8.628M |
| Target Group, Inc. (Canada) | -1.073M |
| NervGen Pharma Corp. | -18.43M |
| Milestone Pharmaceuticals, Inc. | -60.75M |